Ignite Creation Date:
2024-05-06 @ 3:52 AM
Last Modification Date:
2024-10-26 @ 11:40 AM
Study NCT ID:
NCT02395250
Status:
COMPLETED
Last Update Posted:
2019-08-28
First Post:
2015-03-17
Brief Title:
Anti-GPC3 CAR T for Treating Patients With Advanced HCC
Sponsor:
RenJi Hospital
Organization:
RenJi Hospital
Study Overview
Official Title:
Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC
Status:
COMPLETED
Status Verified Date:
2018-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize glypican-3 GPC3 is safe and effective for patients with relapsed or refractory hepatocellular carcinoma HCC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None